首页 > 最新文献

Journal of the Egyptian National Cancer Institute最新文献

英文 中文
Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors 调查乳腺癌患者两种肿瘤和健康乳腺组织中维生素 D 受体基因的表达水平及其与预后因素的关系
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-04-15 DOI: 10.1186/s43046-024-00215-5
Maryam Bahador, Marjan Saeedi Nejad, Shahriar Dabiri, Mohammad Hasan Larizadeh, Maryam Fekri Soofiabadi
Breast cancer is one of the most common cancers known among women. This study aimed to investigate the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors. This descriptive cross-sectional study was conducted in 2022 on 50 patients with high suspicion of breast cancer who were candidates for mastectomy and lumpectomy in a learning hospital. From the patients, two tissue samples were prepared, and there was a total of 100 samples. The samples were subjected to H/E staining and evaluated by a pathologist. The presence or absence of malignancy in each sample was confirmed by two pathologists, and HER2/ER/PR indices were determined. Descriptive and analytical statistical methods and SPSS version 22 software were used. The average age of the patients was 51.60 ± 11.22 years old, and the average tumor size was 3.17 ± 1.28. Most tumors were grade 2 (48%). The expression of HER2, ER, and PR was positive in 24, 64, and 54%, respectively. The largest number of cases were in stage 2A. The expression level of vitamin D receptor (VDR) gene in healthy tissue (2.08 ± 1.01) was higher than tumoral tissue (0.25 ± 1.38) (P = 0.001). In tumoral and healthy tissue, VDR expression was not significant according to tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size. The expression level of VDR in healthy tissue was significantly higher than tumoral tissue. However, there was no significant relationship between VDR and tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size.
乳腺癌是女性最常见的癌症之一。本研究旨在调查乳腺癌患者两种肿瘤和健康乳腺组织中维生素 D 受体基因的表达水平及其与预后因素的关系。这项描述性横断面研究于 2022 年在一家学习型医院进行,对象是 50 名高度怀疑患有乳腺癌的患者,他们都是乳房切除术和肿块切除术的候选者。研究人员从患者身上制备了两份组织样本,共计 100 份样本。样本经 H/E 染色后由病理学家进行评估。每个样本中是否存在恶性肿瘤由两名病理学家确认,并测定 HER2/ER/PR 指数。研究使用了描述性和分析性统计方法以及 SPSS 22 版软件。患者的平均年龄为(51.60±11.22)岁,平均肿瘤大小为(3.17±1.28)颗。大多数肿瘤为 2 级(48%)。HER2、ER和PR呈阳性的比例分别为24%、64%和54%。2A期的病例最多。健康组织中维生素 D 受体(VDR)基因的表达水平(2.08 ± 1.01)高于肿瘤组织(0.25 ± 1.38)(P = 0.001)。在肿瘤组织和健康组织中,VDR的表达与肿瘤分级、HER2、ER、PR、LVI、LN、疾病分期、年龄和肿瘤大小无显著相关性。健康组织中 VDR 的表达水平明显高于肿瘤组织。然而,VDR与肿瘤分级、HER2、ER、PR、LVI、LN、疾病分期、年龄和肿瘤大小之间无明显关系。
{"title":"Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors","authors":"Maryam Bahador, Marjan Saeedi Nejad, Shahriar Dabiri, Mohammad Hasan Larizadeh, Maryam Fekri Soofiabadi","doi":"10.1186/s43046-024-00215-5","DOIUrl":"https://doi.org/10.1186/s43046-024-00215-5","url":null,"abstract":"Breast cancer is one of the most common cancers known among women. This study aimed to investigate the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors. This descriptive cross-sectional study was conducted in 2022 on 50 patients with high suspicion of breast cancer who were candidates for mastectomy and lumpectomy in a learning hospital. From the patients, two tissue samples were prepared, and there was a total of 100 samples. The samples were subjected to H/E staining and evaluated by a pathologist. The presence or absence of malignancy in each sample was confirmed by two pathologists, and HER2/ER/PR indices were determined. Descriptive and analytical statistical methods and SPSS version 22 software were used. The average age of the patients was 51.60 ± 11.22 years old, and the average tumor size was 3.17 ± 1.28. Most tumors were grade 2 (48%). The expression of HER2, ER, and PR was positive in 24, 64, and 54%, respectively. The largest number of cases were in stage 2A. The expression level of vitamin D receptor (VDR) gene in healthy tissue (2.08 ± 1.01) was higher than tumoral tissue (0.25 ± 1.38) (P = 0.001). In tumoral and healthy tissue, VDR expression was not significant according to tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size. The expression level of VDR in healthy tissue was significantly higher than tumoral tissue. However, there was no significant relationship between VDR and tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size.","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"18 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study in left-sided breast cancer treated with moderate deep inspiratory breath hold versus free breathing 左侧乳腺癌患者接受中度深吸气屏气与自由呼吸治疗的比较研究
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-04-08 DOI: 10.1186/s43046-024-00214-6
Anupam Muraleedharan, Sandip Kumar Barik, Deepak Kumar Das, Saroj Kumar Das Majumdar, Bikash Ranjan Mahapatra, Bijay Kumar Barik, Mathan Kumar Ramasubbu, Nehla Haroon K. M., Poornima Devi U., Sk Soel Ahmed, Priyanka Mukherjee, Ashutosh Pattanaik, Avinash Badajena, Minakshi Mishra, Satyabrata Kanungo, Sovan Sarang Dhar, Dillip Kumar Parida
The moderate deep inspiratory breath hold (mDIBH) is a modality famed for cardiac sparing. Prospective studies based on this are few from the eastern part of the world and India. We intend to compare the dosimetry between mDIBH and free-breathing (FB) plans. Thirty-two locally advanced left breast cancer patients were taken up for the study. All patients received a dose of 50 Gy in 25 fractions to the chest wall/intact breast, followed by a 10-Gy boost to the lumpectomy cavity in the case of breast conservation surgery. All the patients were treated in mDIBH using active breath coordinator (ABC). The data from the two dose volume histograms were compared regarding plan quality and the doses received by the organs at risk. Paired t-test was used for data analysis. The dose received by the heart in terms of V5, V10, and V30 (4.55% vs 8.39%) and mean dose (4.73 Gy vs 6.74 Gy) were statistically significant in the ABC group than that in the FB group (all p-values < 0.001). Also, the dose received by the LADA in terms of V30 (19.32% vs 24.87%) and mean dose (32.99 Gy vs 46.65 Gy) were significantly less in the ABC group. The mean treatment time for the ABC group was 20 min, while that for the free-breathing group was 10 min. Incorporating ABC-mDIBH for left-sided breast cancer radiotherapy significantly reduces the doses received by the heart, LADA, and left and right lung, with no compromise in plan quality but with an increase in treatment time.
中度深吸气屏气(mDIBH)是一种著名的心脏疏通方式。在世界东部和印度,基于这种方式的前瞻性研究很少。我们打算比较 mDIBH 和自由呼吸(FB)计划之间的剂量测定。研究对象为 32 名局部晚期左侧乳腺癌患者。所有患者的胸壁/完好乳房都接受了 50 Gy 剂量(25 次分次)的治疗,如果进行了保乳手术,则在肿块切除腔内进行 10 Gy 的增量治疗。所有患者均采用主动呼吸协调器(ABC)进行 mDIBH 治疗。对两种剂量体积直方图的数据进行了比较,以了解计划质量和危险器官所接受的剂量。数据分析采用配对 t 检验。在心脏接受的剂量(V5、V10 和 V30)(4.55% vs 8.39%)和平均剂量(4.73 Gy vs 6.74 Gy)方面,ABC 组比 FB 组有显著的统计学差异(所有 p 值均小于 0.001)。此外,就 V30(19.32% vs 24.87%)和平均剂量(32.99 Gy vs 46.65 Gy)而言,ABC 组的 LADA 接受的剂量也明显低于 FB 组(P 值均小于 0.001)。ABC 组的平均治疗时间为 20 分钟,而自由呼吸组为 10 分钟。在左侧乳腺癌放疗中采用 ABC-mDIBH 技术可大大减少心脏、左侧乳腺组织、左肺和右肺所接受的剂量,同时不会影响计划质量,但会增加治疗时间。
{"title":"A comparative study in left-sided breast cancer treated with moderate deep inspiratory breath hold versus free breathing","authors":"Anupam Muraleedharan, Sandip Kumar Barik, Deepak Kumar Das, Saroj Kumar Das Majumdar, Bikash Ranjan Mahapatra, Bijay Kumar Barik, Mathan Kumar Ramasubbu, Nehla Haroon K. M., Poornima Devi U., Sk Soel Ahmed, Priyanka Mukherjee, Ashutosh Pattanaik, Avinash Badajena, Minakshi Mishra, Satyabrata Kanungo, Sovan Sarang Dhar, Dillip Kumar Parida","doi":"10.1186/s43046-024-00214-6","DOIUrl":"https://doi.org/10.1186/s43046-024-00214-6","url":null,"abstract":"The moderate deep inspiratory breath hold (mDIBH) is a modality famed for cardiac sparing. Prospective studies based on this are few from the eastern part of the world and India. We intend to compare the dosimetry between mDIBH and free-breathing (FB) plans. Thirty-two locally advanced left breast cancer patients were taken up for the study. All patients received a dose of 50 Gy in 25 fractions to the chest wall/intact breast, followed by a 10-Gy boost to the lumpectomy cavity in the case of breast conservation surgery. All the patients were treated in mDIBH using active breath coordinator (ABC). The data from the two dose volume histograms were compared regarding plan quality and the doses received by the organs at risk. Paired t-test was used for data analysis. The dose received by the heart in terms of V5, V10, and V30 (4.55% vs 8.39%) and mean dose (4.73 Gy vs 6.74 Gy) were statistically significant in the ABC group than that in the FB group (all p-values < 0.001). Also, the dose received by the LADA in terms of V30 (19.32% vs 24.87%) and mean dose (32.99 Gy vs 46.65 Gy) were significantly less in the ABC group. The mean treatment time for the ABC group was 20 min, while that for the free-breathing group was 10 min. Incorporating ABC-mDIBH for left-sided breast cancer radiotherapy significantly reduces the doses received by the heart, LADA, and left and right lung, with no compromise in plan quality but with an increase in treatment time.","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"89 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NME1 and DCC variants are associated with susceptibility and tumor characteristics in Mexican patients with colorectal cancer. NME1 和 DCC 变异与墨西哥结直肠癌患者的易感性和肿瘤特征有关。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1186/s43046-024-00213-7
Rosa María Márquez-González, Anilú Margarita Saucedo-Sariñana, César de Jesús Tovar-Jacome, Patricio Barros-Núñez, Martha Patricia Gallegos-Arreola, Mario Humberto Orozco-Gutiérrez, Ignacio Mariscal-Ramírez, Tomas Daniel Pineda-Razo, Aldo Antonio Alcaraz-Wong, María Eugenia Marín-Contreras, Mónica Alejandra Rosales-Reynoso

Background: Colorectal cancer (CRC) ranks third in cancer incidence globally and is the second leading cause of cancer-related mortality. The nucleoside diphosphate kinase 1 (NME1) and netrin 1 receptor (DCC) genes have been associated with resistance against tumorigenesis and tumor metastasis. This study investigates the potential association between NME1 (rs34214448 G > T and rs2302254 C > T) and DCC (rs2229080 G > C and rs714 A > G) variants and susceptibility to colorectal cancer development.

Methods: Samples from 232 colorectal cancer patients and 232 healthy blood donors underwent analysis. Variants were identified using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Associations were assessed using odds ratios (OR), and the p values were adjusted with Bonferroni test.

Results: Individuals carrying the G/T and T/T genotypes for the NME1 rs34214448 variant exhibited a higher susceptibility for develop colorectal cancer (OR = 2.68, 95% CI: 1.76-4.09, P = 0.001 and OR = 2.47, 95% CI: 1.37-4.47, P = 0.001, respectively). These genotypes showed significant associations in patients over 50 years (OR = 2.87, 95% CI: 1.81-4.54, P = 0.001 and OR = 2.99, 95% CI: 1.54-5.79, P = 0.001 respectively) and with early Tumor-Nodule-Metastasis (TNM) stage (P = 0.001), and tumor location in the rectum (P = 0.001). Furthermore, the DCC rs2229080 variant revealed that carriers of the G/C genotype had an increased risk for develop colorectal cancer (OR = 2.00, 95% CI: 1.28-3.11, P = 0.002) and were associated with age over 50 years, sex, and advanced TNM stages (P = 0.001).

Conclusions: These findings suggest that the NME1 rs34214448 and DCC rs2229080 variants play a significant role in colorectal cancer development.

背景:结直肠癌(CRC)在全球癌症发病率中排名第三,是癌症相关死亡的第二大原因。核苷二磷酸激酶 1(NME1)和净蛋白 1 受体(DCC)基因与肿瘤发生和肿瘤转移的抵抗力有关。本研究调查了 NME1(rs34214448 G > T 和 rs2302254 C > T)和 DCC(rs2229080 G > C 和 rs714 A > G)变异与结直肠癌发病易感性之间的潜在关联:对 232 名结直肠癌患者和 232 名健康献血者的样本进行了分析。采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)方法鉴定变异。相关性用几率比(OR)进行评估,P值用Bonferroni检验进行调整:结果:NME1 rs34214448变异的G/T和T/T基因型携带者患结直肠癌的易感性较高(OR=2.68,95% CI:1.76-4.09,P=0.001;OR=2.47,95% CI:1.37-4.47,P=0.001)。这些基因型在 50 岁以上的患者中显示出明显的相关性(OR = 2.87,95% CI:1.81-4.54,P = 0.001 和 OR = 2.99,95% CI:1.54-5.79,P = 0.001),并与早期肿瘤-结节-转移(TNM)分期(P = 0.001)和肿瘤位置在直肠(P = 0.001)相关。此外,DCC rs2229080变异显示,G/C基因型携带者罹患结直肠癌的风险增加(OR = 2.00,95% CI:1.28-3.11,P = 0.002),且与50岁以上年龄、性别和TNM分期晚期有关(P = 0.001):这些研究结果表明,NME1 rs34214448和DCC rs2229080变异在结直肠癌的发展中起着重要作用。
{"title":"NME1 and DCC variants are associated with susceptibility and tumor characteristics in Mexican patients with colorectal cancer.","authors":"Rosa María Márquez-González, Anilú Margarita Saucedo-Sariñana, César de Jesús Tovar-Jacome, Patricio Barros-Núñez, Martha Patricia Gallegos-Arreola, Mario Humberto Orozco-Gutiérrez, Ignacio Mariscal-Ramírez, Tomas Daniel Pineda-Razo, Aldo Antonio Alcaraz-Wong, María Eugenia Marín-Contreras, Mónica Alejandra Rosales-Reynoso","doi":"10.1186/s43046-024-00213-7","DOIUrl":"10.1186/s43046-024-00213-7","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) ranks third in cancer incidence globally and is the second leading cause of cancer-related mortality. The nucleoside diphosphate kinase 1 (NME1) and netrin 1 receptor (DCC) genes have been associated with resistance against tumorigenesis and tumor metastasis. This study investigates the potential association between NME1 (rs34214448 G > T and rs2302254 C > T) and DCC (rs2229080 G > C and rs714 A > G) variants and susceptibility to colorectal cancer development.</p><p><strong>Methods: </strong>Samples from 232 colorectal cancer patients and 232 healthy blood donors underwent analysis. Variants were identified using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Associations were assessed using odds ratios (OR), and the p values were adjusted with Bonferroni test.</p><p><strong>Results: </strong>Individuals carrying the G/T and T/T genotypes for the NME1 rs34214448 variant exhibited a higher susceptibility for develop colorectal cancer (OR = 2.68, 95% CI: 1.76-4.09, P = 0.001 and OR = 2.47, 95% CI: 1.37-4.47, P = 0.001, respectively). These genotypes showed significant associations in patients over 50 years (OR = 2.87, 95% CI: 1.81-4.54, P = 0.001 and OR = 2.99, 95% CI: 1.54-5.79, P = 0.001 respectively) and with early Tumor-Nodule-Metastasis (TNM) stage (P = 0.001), and tumor location in the rectum (P = 0.001). Furthermore, the DCC rs2229080 variant revealed that carriers of the G/C genotype had an increased risk for develop colorectal cancer (OR = 2.00, 95% CI: 1.28-3.11, P = 0.002) and were associated with age over 50 years, sex, and advanced TNM stages (P = 0.001).</p><p><strong>Conclusions: </strong>These findings suggest that the NME1 rs34214448 and DCC rs2229080 variants play a significant role in colorectal cancer development.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"10"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140331841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer. 基于免疫化学的肿瘤浸润淋巴细胞定量和免疫评分作为膀胱癌的预后生物标记物。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-03-25 DOI: 10.1186/s43046-024-00212-8
Sarra Ben Rejeb, Sirine Elfekih, Nadia Kouki, Rami Boulma, Hassen Khouni

Background: Tumor-infiltrating lymphocytes (TILs) and the derived immunoscore (IS) have gained considerable attention over the last decade as prognostic markers in many solid cancers. However, in bladder cancer (BC), their prognostic value is not clearly established.

Methods: The present study aimed to quantify the TILs rates in BC, assess the derived immunoscore, and investigate their prognostic value. An immunochemistry-based quantification of the different subtypes of TILS was performed on paraffin-embedded blocks from patients with invasive urothelial carcinoma of the bladder. We have assessed the rates of TILs, respectively, on peri-tumoral (PT) and intra-tumoral (IT) areas and calculated for each case the corresponding IS which is the index: CD8+/CD3+ TILs. The IS was then classified as low (I0, I1) or high (I2, I3, I4). We included 30 cases in the analysis.

Results: The median age of patients was 65 years with a sex ratio of 9. TILs densities and distribution were significantly variable between IT and PT areas CD3+ (p = 0.03) and CD8+ (p = 0.004) with the highest rates on the PT areas. In univariate analysis, a low density of CD8+ TILs was significantly associated with an advanced age (p = 0.05), with the presence of lympho-vascular invasion (p = 0.02) and with the absence of specific histological subtype (p = 0.05). A low immunoscore was significantly associated with the presence of lympho-vascular invasion (p = 0.004). No significant association was found between TILs subpopulations, the IS, and the other clinicopathological and survival data. The overall survival (OS) and disease-free survival (DFS) medians were slightly superior in highly T (CD3+/CD8+)-cell infiltrated tumors as well as tumors with a high IS densities. However, the univariate analysis showed that TILs and immunoscore did not impact overall survival (OS) and disease-free survival (DFS).

Conclusion: TILs and immunoscore might be effective prognostic tools in BC. However, standardized quantification methods and further investigation on larger samples are highly recommended to definitively attest the prognostic value of TILs and IS in BC.

背景:过去十年中,肿瘤浸润淋巴细胞(TILs)及其衍生的免疫评分(IS)作为许多实体瘤的预后标志物受到了广泛关注。然而,在膀胱癌(BC)中,它们的预后价值尚未明确确立:本研究旨在量化膀胱癌中的TILs率,评估衍生的免疫评分,并探讨其预后价值。我们对膀胱浸润性尿路上皮癌患者的石蜡包埋块进行了基于免疫化学的TILS不同亚型的量化。我们分别对肿瘤周围(PT)和肿瘤内部(IT)区域的 TILs 比率进行了评估,并计算出每个病例的相应 IS 指数:CD8+/CD3+ TILs。然后将 IS 分为低(I0、I1)或高(I2、I3、I4)。我们在分析中纳入了 30 个病例:患者的中位年龄为 65 岁,性别比为 9。TILs 的密度和分布在 IT 区和 PT 区之间存在显著差异,CD3+(p = 0.03)和 CD8+(p = 0.004)在 PT 区的比例最高。在单变量分析中,CD8+ TIL 的低密度与高龄(p = 0.05)、淋巴管侵犯(p = 0.02)和无特定组织学亚型(p = 0.05)明显相关。免疫评分低与淋巴管侵犯的存在明显相关(p = 0.004)。在TILs亚群、IS和其他临床病理及生存数据之间没有发现明显的关联。高T细胞(CD3+/CD8+)浸润肿瘤和高IS密度肿瘤的总生存期(OS)和无病生存期(DFS)中位数略高。然而,单变量分析显示,TILs和免疫评分并不影响总生存期(OS)和无病生存期(DFS):结论:TILs和免疫评分可能是BC有效的预后工具。结论:TILs和免疫评分可能是预测BC预后的有效工具,但要明确TILs和IS在BC中的预后价值,强烈建议采用标准化的定量方法,并对更大样本进行进一步研究。
{"title":"Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.","authors":"Sarra Ben Rejeb, Sirine Elfekih, Nadia Kouki, Rami Boulma, Hassen Khouni","doi":"10.1186/s43046-024-00212-8","DOIUrl":"10.1186/s43046-024-00212-8","url":null,"abstract":"<p><strong>Background: </strong>Tumor-infiltrating lymphocytes (TILs) and the derived immunoscore (IS) have gained considerable attention over the last decade as prognostic markers in many solid cancers. However, in bladder cancer (BC), their prognostic value is not clearly established.</p><p><strong>Methods: </strong>The present study aimed to quantify the TILs rates in BC, assess the derived immunoscore, and investigate their prognostic value. An immunochemistry-based quantification of the different subtypes of TILS was performed on paraffin-embedded blocks from patients with invasive urothelial carcinoma of the bladder. We have assessed the rates of TILs, respectively, on peri-tumoral (PT) and intra-tumoral (IT) areas and calculated for each case the corresponding IS which is the index: CD8+/CD3+ TILs. The IS was then classified as low (I0, I1) or high (I2, I3, I4). We included 30 cases in the analysis.</p><p><strong>Results: </strong>The median age of patients was 65 years with a sex ratio of 9. TILs densities and distribution were significantly variable between IT and PT areas CD3+ (p = 0.03) and CD8+ (p = 0.004) with the highest rates on the PT areas. In univariate analysis, a low density of CD8+ TILs was significantly associated with an advanced age (p = 0.05), with the presence of lympho-vascular invasion (p = 0.02) and with the absence of specific histological subtype (p = 0.05). A low immunoscore was significantly associated with the presence of lympho-vascular invasion (p = 0.004). No significant association was found between TILs subpopulations, the IS, and the other clinicopathological and survival data. The overall survival (OS) and disease-free survival (DFS) medians were slightly superior in highly T (CD3+/CD8+)-cell infiltrated tumors as well as tumors with a high IS densities. However, the univariate analysis showed that TILs and immunoscore did not impact overall survival (OS) and disease-free survival (DFS).</p><p><strong>Conclusion: </strong>TILs and immunoscore might be effective prognostic tools in BC. However, standardized quantification methods and further investigation on larger samples are highly recommended to definitively attest the prognostic value of TILs and IS in BC.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"9"},"PeriodicalIF":1.8,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis. CircMCTP2 通过调控 miR-99a-5p/FZD8 轴促进膀胱癌的进展。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-03-18 DOI: 10.1186/s43046-024-00206-6
Yan Liu, Kexin Zhang, Xianxu Yang

Background: CircRNAs and miRNAs are involved in the progression of tumor. CircMCTP2 is considered as a novel tumor promoter. However, the exact functions of circMCTP2 in bladder cancer are still unclear. This study was designed to explore the underlying mechanisms of circMCTP2-modulated tumor development in bladder cancer.

Methods: The present study is an original research. The levels of circMCTP2 in a total of 39 bladder cancer specimens and cell lines were determined by RT-qPCR. The expression of FZD8 in T24 and RT-4 cells treated with miR-99a-5p mimics were examined using western blotting. In addition, the proliferative, migrative and invasive abilities of transfected cells were determined by CCK8 and Transwell assays. Furthermore, the apoptosis of transfected cells was evaluated using flow cytometry. Dual luciferase reporter assay was performed to elucidate the relationship between miR-99a-5p and circMCTP2/FZD8.

Results: The levels of circMCTP2 were elevated in bladder cancer samples and cells, and this was related to worse survival rate. Downregulation of circMCTP2 suppressed growth and metastasis of cells, whereas the apoptotic rate of cells was enhanced. The levels of miR-99a-5rp was elevated after the downregulation of circMCTP2. Moreover, reverse correlation between the expression of miR-99a-5p and circMCTP2 was revealed in bladder cancer specimens. Additionally, FZD8 was the putative target of miR-99a-5p and the mimics of miR-99a-5p inhibited the proliferation, migration and invasion of bladder cancer cells via the FZD8/Wnt-b-catenin axis. Moreover, circMCTP2 regulated the growth and metastasis of bladder cancer cells potentially through regulating the miR-99a-5p/FZD8/Wnt-b-catenin axis. In summary, circMCTP2 was considered as an oncogenic factor through regulating the miR-99a-5p/FZD8/Wnt-b-catenin axis.

Conclusions: This novel signaling could regulate the biological behaviours of bladder cancer cells, and these findings highlighted circMCTP2 as a critical target for treating bladder cancer.

背景:CircRNA和miRNA参与了肿瘤的进展。circMCTP2被认为是一种新型肿瘤启动子。然而,circMCTP2在膀胱癌中的确切功能仍不清楚。本研究旨在探索 circMCTP2 调节膀胱癌肿瘤发生的潜在机制:本研究为原创性研究。采用 RT-qPCR 方法测定了 39 例膀胱癌标本和细胞系中 circMCTP2 的水平。采用免疫印迹法检测了经 miR-99a-5p 模拟物处理的 T24 和 RT-4 细胞中 FZD8 的表达。此外,还通过 CCK8 和 Transwell 试验测定了转染细胞的增殖、迁移和侵袭能力。此外,还使用流式细胞术评估了转染细胞的凋亡情况。为了阐明 miR-99a-5p 与 circMCTP2/FZD8 之间的关系,还进行了双荧光素酶报告实验:结果:膀胱癌样本和细胞中的 circMCTP2 水平升高,这与生存率降低有关。下调 circMCTP2 可抑制细胞的生长和转移,同时提高细胞的凋亡率。下调 circMCTP2 后,miR-99a-5rp 水平升高。此外,在膀胱癌标本中,miR-99a-5p 和 circMCTP2 的表达呈反向相关。此外,FZD8 是 miR-99a-5p 的假定靶点,miR-99a-5p 的模拟物通过 FZD8/Wnt-b-catenin 轴抑制膀胱癌细胞的增殖、迁移和侵袭。此外,circMCTP2可能通过调节miR-99a-5p/FZD8/Wnt-b-catenin轴来调节膀胱癌细胞的生长和转移。总之,circMCTP2被认为是通过调节miR-99a-5p/FZD8/Wnt-b-catenin轴的致癌因子:结论:这种新的信号传导可调控膀胱癌细胞的生物学行为,这些发现凸显了circMCTP2是治疗膀胱癌的关键靶点。
{"title":"CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis.","authors":"Yan Liu, Kexin Zhang, Xianxu Yang","doi":"10.1186/s43046-024-00206-6","DOIUrl":"10.1186/s43046-024-00206-6","url":null,"abstract":"<p><strong>Background: </strong>CircRNAs and miRNAs are involved in the progression of tumor. CircMCTP2 is considered as a novel tumor promoter. However, the exact functions of circMCTP2 in bladder cancer are still unclear. This study was designed to explore the underlying mechanisms of circMCTP2-modulated tumor development in bladder cancer.</p><p><strong>Methods: </strong>The present study is an original research. The levels of circMCTP2 in a total of 39 bladder cancer specimens and cell lines were determined by RT-qPCR. The expression of FZD8 in T24 and RT-4 cells treated with miR-99a-5p mimics were examined using western blotting. In addition, the proliferative, migrative and invasive abilities of transfected cells were determined by CCK8 and Transwell assays. Furthermore, the apoptosis of transfected cells was evaluated using flow cytometry. Dual luciferase reporter assay was performed to elucidate the relationship between miR-99a-5p and circMCTP2/FZD8.</p><p><strong>Results: </strong>The levels of circMCTP2 were elevated in bladder cancer samples and cells, and this was related to worse survival rate. Downregulation of circMCTP2 suppressed growth and metastasis of cells, whereas the apoptotic rate of cells was enhanced. The levels of miR-99a-5rp was elevated after the downregulation of circMCTP2. Moreover, reverse correlation between the expression of miR-99a-5p and circMCTP2 was revealed in bladder cancer specimens. Additionally, FZD8 was the putative target of miR-99a-5p and the mimics of miR-99a-5p inhibited the proliferation, migration and invasion of bladder cancer cells via the FZD8/Wnt-b-catenin axis. Moreover, circMCTP2 regulated the growth and metastasis of bladder cancer cells potentially through regulating the miR-99a-5p/FZD8/Wnt-b-catenin axis. In summary, circMCTP2 was considered as an oncogenic factor through regulating the miR-99a-5p/FZD8/Wnt-b-catenin axis.</p><p><strong>Conclusions: </strong>This novel signaling could regulate the biological behaviours of bladder cancer cells, and these findings highlighted circMCTP2 as a critical target for treating bladder cancer.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"8"},"PeriodicalIF":1.8,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma. 从分子角度看结直肠癌的全身免疫和伴随免疫
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-03-11 DOI: 10.1186/s43046-024-00211-9
Suman Kumar Ray, Sukhes Mukherjee

The progression of metastasis, a complex systemic disease, is facilitated by interactions between tumor cells and their isolated microenvironments. Over the past few decades, researchers have investigated the metastatic spread of cancer extensively, identifying multiple stages in the process, such as intravasation, extravasation, tumor latency, and the development of micrometastasis and macrometastasis. The premetastatic niche is established in target organs by the accumulation of aberrant immune cells and extracellular matrix proteins. The "seed and soil" idea, which has become widely known and accepted, is being used to this day to guide cancer studies. Changes in the local and systemic immune systems have a major impact on whether an infection spreads or not. The belief that the immune response may play a role in slowing tumor growth and may be beneficial against the metastatic disease underpins the responsiveness shown in the immunological landscape of metastasis. Various hypotheses on the phylogenesis of metastases have been proposed in the past. The primary tumor's secreting factors shape the intratumoral microenvironment and the immune landscape, allowing this progress to be made. Therefore, it is evident that among disseminated tumor cells, there are distinct phenotypes that either carry budding for metastasis or have the ability to obtain this potential or in systemic priming through contact with substantial metastatic niches that have implications for medicinal chemistry. Concurrent immunity signals that the main tumor induces an immune response that may not be strong enough to eradicate the tumor. Immunotherapy's success with some cancer patients shows that it is possible to effectively destroy even advanced-stage tumors by modifying the microenvironment and tumor-immune cell interactions. This review focuses on the metastasome in colorectal carcinoma and the therapeutic implications of site-specific metastasis, systemic priming, tumor spread, and the relationship between the immune system and metastasis.

转移是一种复杂的全身性疾病,肿瘤细胞与其孤立的微环境之间的相互作用促进了转移的进展。过去几十年来,研究人员对癌症的转移扩散进行了广泛的研究,确定了这一过程的多个阶段,如体内浸润、体外浸润、肿瘤潜伏期以及微转移和大转移的发展。转移前生态位是通过异常免疫细胞和细胞外基质蛋白的积累在靶器官中建立起来的。种子和土壤 "的观点已广为人知并被接受,至今仍被用于指导癌症研究。局部和全身免疫系统的变化对感染是否扩散有重大影响。人们认为,免疫反应可能在减缓肿瘤生长方面发挥作用,并可能对转移性疾病有益,这也是转移性疾病的免疫学特征所显示的反应性的基础。过去曾提出过各种关于转移瘤系统发育的假说。原发肿瘤的分泌因子塑造了瘤内微环境和免疫环境,使这种进展得以实现。因此,很明显,在播散的肿瘤细胞中,存在着不同的表型,这些表型要么带有转移萌芽,要么有能力获得这种潜能,或者通过与实质性转移壁龛的接触进行系统性引诱,这对药物化学具有影响。并发免疫信号表明,主肿瘤诱导的免疫反应可能还不足以根除肿瘤。免疫疗法在一些癌症患者身上取得的成功表明,通过改变微环境和肿瘤与免疫细胞的相互作用,即使是晚期肿瘤也有可能被有效消灭。这篇综述将重点讨论结直肠癌的转移体,以及特定部位转移、系统性引诱、肿瘤扩散和免疫系统与转移之间关系的治疗意义。
{"title":"Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma.","authors":"Suman Kumar Ray, Sukhes Mukherjee","doi":"10.1186/s43046-024-00211-9","DOIUrl":"10.1186/s43046-024-00211-9","url":null,"abstract":"<p><p>The progression of metastasis, a complex systemic disease, is facilitated by interactions between tumor cells and their isolated microenvironments. Over the past few decades, researchers have investigated the metastatic spread of cancer extensively, identifying multiple stages in the process, such as intravasation, extravasation, tumor latency, and the development of micrometastasis and macrometastasis. The premetastatic niche is established in target organs by the accumulation of aberrant immune cells and extracellular matrix proteins. The \"seed and soil\" idea, which has become widely known and accepted, is being used to this day to guide cancer studies. Changes in the local and systemic immune systems have a major impact on whether an infection spreads or not. The belief that the immune response may play a role in slowing tumor growth and may be beneficial against the metastatic disease underpins the responsiveness shown in the immunological landscape of metastasis. Various hypotheses on the phylogenesis of metastases have been proposed in the past. The primary tumor's secreting factors shape the intratumoral microenvironment and the immune landscape, allowing this progress to be made. Therefore, it is evident that among disseminated tumor cells, there are distinct phenotypes that either carry budding for metastasis or have the ability to obtain this potential or in systemic priming through contact with substantial metastatic niches that have implications for medicinal chemistry. Concurrent immunity signals that the main tumor induces an immune response that may not be strong enough to eradicate the tumor. Immunotherapy's success with some cancer patients shows that it is possible to effectively destroy even advanced-stage tumors by modifying the microenvironment and tumor-immune cell interactions. This review focuses on the metastasome in colorectal carcinoma and the therapeutic implications of site-specific metastasis, systemic priming, tumor spread, and the relationship between the immune system and metastasis.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"7"},"PeriodicalIF":1.8,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing an efficient method for melanoma detection using CNN techniques 利用 CNN 技术开发高效的黑色素瘤检测方法
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-02-26 DOI: 10.1186/s43046-024-00210-w
Devika Moturi, Ravi Kishan Surapaneni, Venkata Sai Geethika Avanigadda
More and more genetic and metabolic abnormalities are now known to cause cancer, which is typically deadly. Any bodily part may become infected by cancerous cells, which can be fatal. Skin cancer is one of the most prevalent types of cancer, and its prevalence is rising across the globe. Squamous and basal cell carcinomas, as well as melanoma, which is clinically aggressive and causes the majority of deaths, are the primary subtypes of skin cancer. Screening for skin cancer is therefore essential. The best way to quickly and precisely detect skin cancer is by using deep learning techniques. In this research deep learning techniques like MobileNetv2 and Dense net will be used for detecting or identifying two main kinds of tumors malignant and benign. For this research HAM10000 dataset is considered. This dataset consists of 10,000 skin lesion images and the disease comprises nonmelanocytic and melanocytic tumors. These two techniques can be used for detecting the malignant and benign. All these methods are compared and then a result can be inferred from their performance. After the model evaluation, the accuracy for the MobileNetV2 was 85% and customized CNN was 95%. A web application has been developed with the Python framework that provides a graphical user interface with the best-trained model. The graphical user interface allows the user to enter the patient details and upload the lesion image. The image will be classified with the appropriate trained model which can predict whether the uploaded image is cancerous or non-cancerous. This web application also displays the percentage of cancer affected. As per the comparisons between the two techniques customized CNN gives higher accuracy for the detection of melanoma.
现在已知越来越多的基因和代谢异常会导致癌症,而癌症通常是致命的。身体的任何部位都可能受到癌细胞的感染,从而导致死亡。皮肤癌是最常见的癌症类型之一,其发病率在全球呈上升趋势。鳞状细胞癌、基底细胞癌和黑色素瘤是皮肤癌的主要亚型,黑色素瘤在临床上具有侵袭性,导致大多数人死亡。因此,皮肤癌筛查至关重要。快速、精确地检测皮肤癌的最佳方法是使用深度学习技术。在这项研究中,MobileNetv2 和 Dense net 等深度学习技术将用于检测或识别恶性和良性两大类肿瘤。本研究考虑使用 HAM10000 数据集。该数据集由 10,000 张皮肤病变图像组成,疾病包括非黑色素细胞肿瘤和黑色素细胞肿瘤。这两种技术可用于检测恶性肿瘤和良性肿瘤。对所有这些方法进行比较后,可以从它们的性能中推断出结果。经过模型评估,MobileNetV2 的准确率为 85%,定制 CNN 的准确率为 95%。使用 Python 框架开发的网络应用程序提供了一个图形用户界面,其中包含最佳训练模型。图形用户界面允许用户输入患者详细信息并上传病变图像。图像将由经过适当训练的模型进行分类,该模型可预测上传的图像是癌变还是非癌变。该网络应用程序还能显示癌症发病率。根据两种技术的比较,定制的 CNN 检测黑色素瘤的准确率更高。
{"title":"Developing an efficient method for melanoma detection using CNN techniques","authors":"Devika Moturi, Ravi Kishan Surapaneni, Venkata Sai Geethika Avanigadda","doi":"10.1186/s43046-024-00210-w","DOIUrl":"https://doi.org/10.1186/s43046-024-00210-w","url":null,"abstract":"More and more genetic and metabolic abnormalities are now known to cause cancer, which is typically deadly. Any bodily part may become infected by cancerous cells, which can be fatal. Skin cancer is one of the most prevalent types of cancer, and its prevalence is rising across the globe. Squamous and basal cell carcinomas, as well as melanoma, which is clinically aggressive and causes the majority of deaths, are the primary subtypes of skin cancer. Screening for skin cancer is therefore essential. The best way to quickly and precisely detect skin cancer is by using deep learning techniques. In this research deep learning techniques like MobileNetv2 and Dense net will be used for detecting or identifying two main kinds of tumors malignant and benign. For this research HAM10000 dataset is considered. This dataset consists of 10,000 skin lesion images and the disease comprises nonmelanocytic and melanocytic tumors. These two techniques can be used for detecting the malignant and benign. All these methods are compared and then a result can be inferred from their performance. After the model evaluation, the accuracy for the MobileNetV2 was 85% and customized CNN was 95%. A web application has been developed with the Python framework that provides a graphical user interface with the best-trained model. The graphical user interface allows the user to enter the patient details and upload the lesion image. The image will be classified with the appropriate trained model which can predict whether the uploaded image is cancerous or non-cancerous. This web application also displays the percentage of cancer affected. As per the comparisons between the two techniques customized CNN gives higher accuracy for the detection of melanoma.","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"175 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139969415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia. 成人急性白血病中白血病爆破细胞表达 OCT3/4 和 SOX2 抗原的意义。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-02-12 DOI: 10.1186/s43046-024-00209-3
Salah Aref, Omnyia Khaled, Nadia El Menshawy, Emad Azmy, Mohamed Aref, Osama Salama, Nada Khaled

Objective: This study aimed to address the prognostic impact of SOX2 and OCT3/4 expression on adult acute leukemia patients' outcomes.

Methods: SOX2 and OCT3/4 expression by blast cells were evaluated by flow cytometry in 80 acute leukemia patients and 8 healthy controls.

Results: Baseline SOX2 and OCT3/4 expression were significantly higher in both ALL (P = < 0.001, P = 0.005 respectively) and AML patients (P < 0.001, P = 0.003 respectively) as compared to control, and decline at complete remission (CR) and elevated again at relapse. High SOX2 and OCT3/4 levels were significantly correlated with the presence of adverse risk stratification parameters.

Conclusion: Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.

研究目的本研究旨在探讨SOX2和OCT3/4的表达对成人急性白血病患者预后的影响:方法:通过流式细胞术评估了80名急性白血病患者和8名健康对照者的囊泡细胞中SOX2和OCT3/4的表达情况:结果:SOX2和OCT3/4的基线表达在两种急性白血病患者中均显著升高(P = 结论:SOX2和OCT3/4的基线表达在两种急性白血病患者中均显著升高:我们的研究结果表明,SOX2和OCT3/4可作为生物标记物,改善急性白血病患者的风险分层。此外,SOX2和OCT3/4都可能是治疗靶点,尤其是在耐药性急性白血病中。
{"title":"Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia.","authors":"Salah Aref, Omnyia Khaled, Nadia El Menshawy, Emad Azmy, Mohamed Aref, Osama Salama, Nada Khaled","doi":"10.1186/s43046-024-00209-3","DOIUrl":"10.1186/s43046-024-00209-3","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to address the prognostic impact of SOX2 and OCT3/4 expression on adult acute leukemia patients' outcomes.</p><p><strong>Methods: </strong>SOX2 and OCT3/4 expression by blast cells were evaluated by flow cytometry in 80 acute leukemia patients and 8 healthy controls.</p><p><strong>Results: </strong>Baseline SOX2 and OCT3/4 expression were significantly higher in both ALL (P = < 0.001, P = 0.005 respectively) and AML patients (P < 0.001, P = 0.003 respectively) as compared to control, and decline at complete remission (CR) and elevated again at relapse. High SOX2 and OCT3/4 levels were significantly correlated with the presence of adverse risk stratification parameters.</p><p><strong>Conclusion: </strong>Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"5"},"PeriodicalIF":1.8,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet-to-albumin ratio and radiation-induced lymphopenia-prognostic biomarker for carcinoma esophagus. 血小板白蛋白比值和辐射诱导的淋巴细胞减少症--食管癌的预后生物标志物
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-02-05 DOI: 10.1186/s43046-024-00208-4
Adrija Ghosh, Abhilash Dagar, Ram Pukar Bharat, Jaswin Raj, Dyuti Shah, Jyoti Sharma, Akash Kumar, Pritee A Patil, Aman Sharma, Dayanand Sharma, Supriya Mallick

Background: Esophageal cancer has a poor survival outcome with 5-year OS at 16.7% despite treatment. Some inflammation-based prognostic indicators like the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been previously studied as potential biomarker for predicting outcome in esophageal cancer. Recently, platelet-to-albumin ratio (PAR) has been reported as a promising prognostic factor in gastrointestinal malignancies.

Methods: We performed a retrospective analysis of prospectively treated patients of carcinoma esophagus to evaluate the prognostic significance of inflammation-based prognostic indicators-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and a composite inflammation-nutrition index: platelet-to-albumin ratio (PAR) in esophageal cancer. Based on previous studies, the optimal cut-off value of PAR was kept at 5.7 × 10^9, and 2.62 for NLR.

Results: A total of 71 patients of locally advanced esophageal cancer treated between 2019 and 2022, with either neoadjuvant or definitive chemoradiotherapy, were included. Median follow-up time was 19 months [range: 7-44 months]. Median OS and PFS in our study cohort were 11.3 months [range: 7-23 months] and 7.8 months [range: 3-17 months], respectively. In univariate analysis, lower PAR was found to be significantly correlated with shorter survival time (HR = 2.41; 1.3-4.76; p = 0.047). There was no association found between the OS and the NLR [HR = 1.09; 0.95-1.26; p = 0.222]. Univariate and multivariate linear and logistic regressions found no association between V15, V10, V5, or V2 of spleen and nadir lymphocyte count or between Dmax or Dmean and nadir lymphocyte counts.

Conclusion: Present analysis found a trend toward an inverse association between PAR and OS. PAR, in the not-so-distant future, may evolve as a novel, convenient, and inexpensive prognostic indicator in esophageal cancer.

背景食管癌的生存率很低,尽管接受了治疗,但5年生存率仅为16.7%。以前曾研究过一些基于炎症的预后指标,如中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),作为预测食管癌预后的潜在生物标志物。最近,有报道称血小板与白蛋白比值(PAR)是胃肠道恶性肿瘤中一种有希望的预后因素:我们对经过前瞻性治疗的食管癌患者进行了回顾性分析,以评估食管癌中基于炎症的预后指标--中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)以及炎症-营养综合指数:血小板与白蛋白比值(PAR)--的预后意义。根据以往的研究,PAR 的最佳临界值为 5.7 × 10^9,NLR 为 2.62:共纳入了 71 名在 2019 年至 2022 年期间接受新辅助或确定性化放疗的局部晚期食管癌患者。中位随访时间为19个月[范围:7-44个月]。我们研究队列的中位OS和PFS分别为11.3个月[范围:7-23个月]和7.8个月[范围:3-17个月]。在单变量分析中发现,较低的 PAR 与较短的生存时间显著相关(HR = 2.41;1.3-4.76;P = 0.047)。OS 与 NLR 之间没有相关性[HR = 1.09; 0.95-1.26; p = 0.222]。单变量和多变量线性及逻辑回归发现,脾脏的V15、V10、V5或V2与最低淋巴细胞计数之间以及Dmax或Dmean与最低淋巴细胞计数之间均无关联:目前的分析发现,PAR与OS之间呈负相关趋势。在不远的将来,PAR 可能会成为食管癌预后的一个新颖、方便、廉价的指标。
{"title":"Platelet-to-albumin ratio and radiation-induced lymphopenia-prognostic biomarker for carcinoma esophagus.","authors":"Adrija Ghosh, Abhilash Dagar, Ram Pukar Bharat, Jaswin Raj, Dyuti Shah, Jyoti Sharma, Akash Kumar, Pritee A Patil, Aman Sharma, Dayanand Sharma, Supriya Mallick","doi":"10.1186/s43046-024-00208-4","DOIUrl":"10.1186/s43046-024-00208-4","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer has a poor survival outcome with 5-year OS at 16.7% despite treatment. Some inflammation-based prognostic indicators like the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been previously studied as potential biomarker for predicting outcome in esophageal cancer. Recently, platelet-to-albumin ratio (PAR) has been reported as a promising prognostic factor in gastrointestinal malignancies.</p><p><strong>Methods: </strong>We performed a retrospective analysis of prospectively treated patients of carcinoma esophagus to evaluate the prognostic significance of inflammation-based prognostic indicators-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and a composite inflammation-nutrition index: platelet-to-albumin ratio (PAR) in esophageal cancer. Based on previous studies, the optimal cut-off value of PAR was kept at 5.7 × 10^9, and 2.62 for NLR.</p><p><strong>Results: </strong>A total of 71 patients of locally advanced esophageal cancer treated between 2019 and 2022, with either neoadjuvant or definitive chemoradiotherapy, were included. Median follow-up time was 19 months [range: 7-44 months]. Median OS and PFS in our study cohort were 11.3 months [range: 7-23 months] and 7.8 months [range: 3-17 months], respectively. In univariate analysis, lower PAR was found to be significantly correlated with shorter survival time (HR = 2.41; 1.3-4.76; p = 0.047). There was no association found between the OS and the NLR [HR = 1.09; 0.95-1.26; p = 0.222]. Univariate and multivariate linear and logistic regressions found no association between V15, V10, V5, or V2 of spleen and nadir lymphocyte count or between Dmax or Dmean and nadir lymphocyte counts.</p><p><strong>Conclusion: </strong>Present analysis found a trend toward an inverse association between PAR and OS. PAR, in the not-so-distant future, may evolve as a novel, convenient, and inexpensive prognostic indicator in esophageal cancer.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"4"},"PeriodicalIF":1.8,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139681318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center. 晚期 NSCLC 中 PD-L1 的表达及其意义:一家三级医疗中心的实际经验。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-01-29 DOI: 10.1186/s43046-024-00207-5
Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ghanashyam Biswas

Background: Targeted therapies against programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC) have revolutionized the management in recent years. There is paucity of data on the significance of PD-L1 expression in NSCLC from India. We aimed to study the prevalence of PD-L1 expression and its relation with different clinico-pathological parameters in advanced NSCLC from a tertiary care center in Eastern India.

Methods: All consecutive patients with advanced NSCLC diagnosed from January 2020 to December 2021 were prospectively evaluated for PD-L1 expression in formalin fixed-paraffin embedded tumor tissue specimens using immunohistochemistry analysis. A PD-L1 expression of < 1%, 1-49%, and ≥ 50% were considered negative, low, and high expression positive respectively, and association with various parameters was performed.

Results: Out of the 94 patients (mean age 59.6 ± 14 years and 63.8% males), PD-L1 positivity was seen in 42 (44.7%) patients, with low positivity (1-49%) in 29 patients and high positivity (≥ 50%) in 13 patients. Epidermal Growth Factor Receptor (EGFR) mutations were seen in 28 patients (29.8%). There were no significant differences in PD-L1 positivity with respect to gender, age, and molecular mutation status. PD-L1 positivity was significantly associated with tobacco use (p = 0.04), advanced tumor stage (p < 0.001), and higher nodal stage (p < 0.001). Median overall survival in the cohort was 17 months and it was not significantly different between the PD-L1 positive and negative groups.

Conclusions: Forty-five percent of advanced NSCLC patients in our cohort showed positive PD-L1 expression and it is associated with tobacco use and aggressive tumor characteristics.

背景:近年来,针对非小细胞肺癌(NSCLC)中程序性死亡配体-1(PD-L1)的靶向疗法彻底改变了治疗方法。印度有关 NSCLC 中 PD-L1 表达重要性的数据很少。我们旨在研究印度东部一家三级医疗中心的晚期 NSCLC 中 PD-L1 表达的流行率及其与不同临床病理参数的关系:2020年1月至2021年12月期间确诊的所有晚期NSCLC连续患者均接受了福尔马林固定-石蜡包埋肿瘤组织标本中PD-L1表达的前瞻性评估,采用免疫组化分析。结果显示,PD-L1 的表达率为在 94 例患者(平均年龄为 59.6 ± 14 岁,男性占 63.8%)中,42 例(44.7%)患者的 PD-L1 呈阳性,其中 29 例患者的 PD-L1 呈低阳性(1-49%),13 例患者的 PD-L1 呈高阳性(≥ 50%)。28名患者(29.8%)出现表皮生长因子受体(EGFR)突变。PD-L1阳性率与性别、年龄和分子突变状态无明显差异。在我们的队列中,45%的晚期NSCLC患者PD-L1呈阳性表达,这与吸烟和侵袭性肿瘤特征有关。
{"title":"PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center.","authors":"Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ghanashyam Biswas","doi":"10.1186/s43046-024-00207-5","DOIUrl":"10.1186/s43046-024-00207-5","url":null,"abstract":"<p><strong>Background: </strong>Targeted therapies against programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC) have revolutionized the management in recent years. There is paucity of data on the significance of PD-L1 expression in NSCLC from India. We aimed to study the prevalence of PD-L1 expression and its relation with different clinico-pathological parameters in advanced NSCLC from a tertiary care center in Eastern India.</p><p><strong>Methods: </strong>All consecutive patients with advanced NSCLC diagnosed from January 2020 to December 2021 were prospectively evaluated for PD-L1 expression in formalin fixed-paraffin embedded tumor tissue specimens using immunohistochemistry analysis. A PD-L1 expression of < 1%, 1-49%, and ≥ 50% were considered negative, low, and high expression positive respectively, and association with various parameters was performed.</p><p><strong>Results: </strong>Out of the 94 patients (mean age 59.6 ± 14 years and 63.8% males), PD-L1 positivity was seen in 42 (44.7%) patients, with low positivity (1-49%) in 29 patients and high positivity (≥ 50%) in 13 patients. Epidermal Growth Factor Receptor (EGFR) mutations were seen in 28 patients (29.8%). There were no significant differences in PD-L1 positivity with respect to gender, age, and molecular mutation status. PD-L1 positivity was significantly associated with tobacco use (p = 0.04), advanced tumor stage (p < 0.001), and higher nodal stage (p < 0.001). Median overall survival in the cohort was 17 months and it was not significantly different between the PD-L1 positive and negative groups.</p><p><strong>Conclusions: </strong>Forty-five percent of advanced NSCLC patients in our cohort showed positive PD-L1 expression and it is associated with tobacco use and aggressive tumor characteristics.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"3"},"PeriodicalIF":1.8,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Egyptian National Cancer Institute
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1